Botox — Hyperhidrosis

Botulinum toxin (Botox) injections for primary axillary hyperhidrosis — excessive underarm sweating. Precisely placed intradermal injections block acetylcholine release at sweat glands, reducing perspiration by 80-90% for 6-9 months.

Botulinum toxin treatment for hyperhidrosis at Dermedika addresses primary axillary hyperhidrosis — a condition characterised by excessive, uncontrollable sweating in the underarm area that occurs independently of heat or physical exertion and has a significant impact on daily life, professional confidence, and clothing choices. The treatment involves a series of small, precisely placed intradermal injections of botulinum toxin type A into the skin of both axillae, targeting the eccrine sweat glands that produce excessive perspiration. Botulinum toxin blocks the release of acetylcholine from sympathetic nerve terminals at the neuromuscular junction of the sweat glands. Without acetylcholine signalling, the glands cannot respond to stimulation and perspiration in the treated area is dramatically reduced. Clinical studies consistently show an 80-90% reduction in axillary sweating following a properly administered treatment, with results typically detectable within 5-7 days of the procedure. The treatment protocol involves mapping the hyperhidrotic area using the Minor iodine-starch test (which marks active sweat gland zones by turning blue-black on contact with sweat) and then administering 15-20 injections per axilla at defined grid intervals. Topical anaesthetic and ice are used to maximise comfort; the sensation during injection is minimal due to the very fine needle gauge used. The session covers both underarms within a single appointment at the quoted 1800 PLN price. Results last 6-9 months on average, after which the nerve terminals regenerate and sweating gradually returns to its previous level. Repeat treatment maintains the effect continuously. Unlike antiperspirant products, botulinum toxin does not block pores or cause skin irritation, and there is no systemic effect — compensatory sweating (increased sweating at untreated sites) is not a reported concern with axillary treatment at standard doses.